Why the Same Technology Isn’t Used the Same Way Everywhere
Imaging technology has transformed modern medicine. Its adoption is far from uniform. Culture, history, and healthcare structure shape what clinicians reach for, and when.
Juan Vegarra
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Walk into a catheterization lab in Tokyo and you’ll encounter something that might surprise a cardiologist trained in the United States: a team methodically reviewing CT angiography images, OCT pullbacks, and intravascular ultrasound data before a stent is ever deployed. This isn’t unusual in Japan. It’s standard practice. Walk into a comparable lab in the American Midwest, and the workflow looks markedly different. The technology exists in both rooms. The cultures using it do not.
This gap isn’t explained by budget or access alone. It cuts to something deeper: the values, risk philosophies, and historical experiences that shape how clinicians and healthcare systems think about diagnostic certainty, surgical intervention, and the role of technology in the care relationship.
22% CT angiography use before PCI in Japan [1] | 2% CT angiography use before PCI in the U.S. [1] | 1:7 CABG-to-PCI ratio in Japan vs. ~1:3 in the U.S. [2] |
The Japan case: imaging as a clinical foundation
Japan’s relationship with intracoronary imaging goes well beyond convenience. It reflects a broader clinical philosophy. One that prizes procedural precision, values visualization as a precondition for intervention, and views catheter-based treatment as a preferred alternative to open surgery whenever possible.
Japanese interventional cardiologists perform elective PCI at more than twice the rate of their American counterparts [3]. That preference for minimally invasive treatment creates a feedback loop. If you’re going to stent complex lesions that elsewhere might go to surgery, you need the best possible imaging to do it safely. OCT and IVUS aren’t optional. They’re the clinical foundation that makes aggressive catheter-based treatment defensible.
Cultural attitudes toward open-heart surgery reinforce this dynamic. Patient reluctance to undergo sternotomy in Japan is well-documented, and it isn’t simply squeamishness. It reflects a broader societal value around bodily integrity, recovery burden, and the doctor-patient compact. The result is a healthcare system that has built its coronary intervention infrastructure around imaging-guided, minimally invasive approaches, and trained generations of physicians to practice within it.
“The technology exists in both rooms. The cultures using it do not.” |
The United States: volume, velocity, and the weight of history
American cardiology has historically been oriented around throughput and acute-care excellence. The U.S. leads the world in outcomes for emergent revascularization. Door-to-balloon times, STEMI protocols, and post-MI survival are areas of genuine global strength. In the elective setting, the picture is more complicated.
Stress testing, including nuclear perfusion imaging and stress echo, remains the dominant pre-procedural workup in the U.S., used in over half of elective PCI cases. Japan uses it in fewer than 15% [4]. In Japan, CT angiography has become the pre-procedural standard, offering anatomical detail that physiological stress tests cannot match.
The comparative effectiveness literature on imaging-guided versus stress-test-guided approaches continues to develop. Adoption patterns reflect both the current state of the evidence, and the systems built around earlier practice: training pathways, reimbursement infrastructure, and established referral relationships that don’t rewire overnight. Neither culture is wrong on its own terms. They are optimizing for different things, with different histories.
Five regions, five philosophies
Imaging adoption is not a single story. It is five stories (at least), each shaped by a distinct set of clinical traditions, training pipelines, and institutional pressures.
EAST ASIA Japan & South Korea Deep investment in intracoronary imaging (OCT, IVUS). Minimally invasive preference drives imaging adoption. Physician identity tied to procedural mastery and visualization. Imaging sits at the center of the clinical decision, not adjacent to it. Imaging-first culture |
WESTERN EUROPE Germany & the Netherlands Strong evidence-based tradition. Heart-team decision-making is institutionalized. Guideline compliance creates consistent but conservative adoption of novel imaging. New technologies enter the clinic when the evidence is in; they rarely enter ahead of it. Evidence-gated adoption |
NORTH AMERICA United States & Canada Acute-care excellence; elective practice more variable. Reimbursement pathways and training history shape imaging uptake in ways that can lag the evidence. Regional and institutional variation is substantial. High-volume centers may operate very differently from community labs even within the same health system. Volume-driven, variable |
MIDDLE EAST & SOUTHEAST ASIA Gulf, Singapore, and regional hubs Technology-forward centers of excellence in Riyadh, Abu Dhabi, Dubai, Singapore, and elsewhere. International physician training creates hybrid practice patterns that blend Western evidence frameworks with local clinical priorities. Flagship programs often adopt advanced imaging early and build training programs around it. Technology-forward centers of excellence |
LATIN AMERICA Brazil, Mexico & the Andean region Rapidly expanding catheterization infrastructure anchored by academic centers in São Paulo, Mexico City, Bogotá, and Lima. A growing interventional cardiology community with strong ties to both Europe and the U.S. shapes practice patterns that draw from multiple traditions. Academic leadership sets the pace, and regional societies play a central role in diffusing new techniques. Expanding infrastructure, academic leadership |
What this means for medical technology
For any company developing imaging technology, the lesson from these regional patterns is both humbling and actionable. Clinical evidence, necessary as it is, does not uniformly translate into adoption. A device with strong trial data will face different barriers in Osaka than in Houston, and different again in Riyadh, São Paulo, or Warsaw.
Market development in MedTech requires genuine cultural literacy. That means understanding not just which physicians to reach, but how their training shaped their relationship with imaging, what their patients expect, how their reimbursement environment rewards or penalizes diagnostic thoroughness, and what role the heart team plays in treatment decisions.
In Japan, the opinion leader is likely an interventionalist who thinks visually. In Germany, she may be a cardiologist steeped in guideline committees. In the Gulf, he may be a fellowship-trained physician who trained abroad and now leads a flagship program. In Brazil, the academic center cardiologist balances local practice realities with global evidence networks.
Getting this wrong is expensive. Getting it right, by tailoring not just the message but the entire market development approach to regional clinical culture, is the difference between a technology that achieves its potential and one that stalls in the adoption curve despite genuine clinical merit.
Imaging in new indications: the culture question compounds
When imaging technology moves into adjacent or novel indications, the cultural dynamics become even more consequential. Established indications carry established workflows, reimbursement codes, and training programs. Novel indications carry none of these.
Clinical culture fills the vacuum. Physician openness to expanding the role of imaging, patient familiarity with the concept, and institutional willingness to invest in new training are all culturally mediated variables.
Understanding this dynamic early, before market launch and during opinion-leader engagement and evidence development, is not merely strategic. It is the precondition for building a market that lasts.